CPHI South East Asia’s Post

🗓️ Yesterday i had the oppurtunity to attend 1st SFEE Summit organised by The Hellenic Association of Pharmaceutical Companies (SFEE) at the📍Megaron International Conference Center in Athens. 🇬🇷 🔍 Theme: “Redefining Value” and 📈 Focus Areas: • Greek Economy: Exploring the value of the pharmaceutical industry • Innovation: Discussing the role of pharmaceutical innovation • Healthcare Trends: Unveiling the latest trends in healthcare and pharma • Challenges & Opportunities: Addressing the Greek pharma sector’s challenges and opportunities 🚀 It was a great summit which facilitated in-depth discussions, explored solutions, and shared best practices to current challenges in pharmaceutical landscape while shaped the future of the pharmaceutical policy in Greece 🌿 🔗Last but not least, it was a great oppurtunity to connect with colleagues across healthcare industry during networking breaks #SfEE #SfEESummit #RedifingValue

#CPHI Milano 2024: at the heart of the #pharmaceuticalindustry The world's leading trade fair for the pharmaceutical industry, will return to #Milan from 8 to 10 October 2024 at #FieraMilanoRho. With over 62,000 participants, more than 166 countries represented and 2,400 exhibitors, the 2024 edition of CPHI Milan promises to be the largest ever. An unmissable opportunity for your business: 🔹 Comprehensive overview of the entire pharmaceutical supply chain. 🔹 Italy: one of the leading producers and exporters of pharmaceutical ingredients in Europe. 🔹 A global event in a strategic region. Lombardy the beating heart of Italian pharmaceutical production: a hub for pharmaceutical research, development and production. 🔹 #FieraMilano: the ideal venue for a global event like CPHI. 🔹Ideal platform for launching new therapies and improving patient health globally. If you want to know more, we also talk about it in the latest article on our website - link in the first comment

📅 Join us tomorrow at 11:00 a.m. ET for our "Digital Measurement of Nocturnal Scratch: New Developments" webinar series. The session will focus on the most recent regulatory feedback garnered through FDA's Critical Path Innovation Meeting forum and the EMA's Innovation Task Force (ITF) briefing meetings under the EMA pilot conducted with EFPIA - European Federation of Pharmaceutical Industries and Associations and DEEP Measures. Hear from industry experts: 🎙️ Dr. Thorsten Vetter, EMA 🎙️ Beth Kunkoski, FDA 🎙️ Matthew Diamond, FDA 🎙️ Carrie Northcott, Pfizer 🎙️ Michael Benecky, UCB 🎙️ Lada Leyens, DEEP Measures 🔍 Be part of this vital discussion as we chart a course toward a future where digital measurements guide us toward a deeper understanding of patients' conditions and everyday experiences. https://lnkd.in/edQ6BMsG European Medicines Agency EMA National Eczema Association GSK Pfizer ActiGraph Massachusetts Institute of Technology Emerald Innovations Biofourmis DEEP Measures Takeda UCB Northwestern University Sonica Health Genentech Digital Medicine Society (DiMe)

CPHI China stands as a cornerstone event for pharmaceutical companies worldwide, offering a premier platform for networking, collaboration, and business expansion. This annual gathering brings together key players from the pharmaceutical industry, spanning from manufacturers and suppliers to distributors and buyers. The allure of CPHI China lies in its unparalleled opportunities for forging new partnerships, discovering the latest innovations, and accessing emerging markets. With a diverse array of exhibitors showcasing cutting-edge products and services, attendees gain invaluable insights into industry trends and market dynamics. Moreover, CPHI China serves as a hub for fostering strategic alliances and cultivating international connections, paving the way for enhanced market penetration and sustained growth. By participating in this prestigious event, pharmaceutical companies can harness the power of collaboration to propel their businesses to new heights, making CPHI China an indispensable cornerstone of success in the global pharmaceutical landscape. #pharmanetworking #CPHIChina #Pharmainnovation #CPHIConncetions #Pharmacollaboration #CPHI2024 #PharmaEvents #CPHITradefair Yashoda Ganesh Khan Imran Ajaz Raien #pharmaleadership #pharmalife #clinicaltrials #pharmanews #biotech #pharmamanufacturing #API #biopharma

6th FOP Drug Development Forum: Call for oral presentations and posters with unpublished data or data not published before January 1, 2023. Deadline is February 19: https://lnkd.in/dfrq8sYC The DDF brings together biotech and pharmaceutical companies, academic researchers and clinician scientists to collaborate and advance FOP research. It's an opportunity to discuss emerging FOP data and highlight gaps in our understanding of FOP disease pathogenesis that could offer new therapeutic options. Early registration deadline is March 1. Rates increase $100 on March 2: ifopa.org/2024_fop_ddf Due to the nature of the content, the DDF is a meeting designed only for researchers, clinician scientists, pharmaceutical/biotech employees, and employees of regulatory agencies. The sessions are not posted publicly - you must be registered to attend in person or watch online.

💡 Spotlight on Today's LISA Hero: Alexander Herzog 💡 Alexander is Secretary General at PHARMIG, the Association of the Austrian Pharmaceutical Industry. He is also Member of the Council at IFPMA - International Federation of Pharmaceutical Manufacturers & Associations and Member of the Advisory Board of LISA - Life Science Austria. 🎤 Alexander, what is your role in the Life Science ecosystem? 🔊 In PHARMIG, we represent the entire pharmaceutical industry in Austria, from small companies to large corporations, whether research or sales subsidiaries. We do everything in our power to strengthen Austria as a pharmaceutical location and to keep it internationally competitive. Because one thing is clear to us and we always focus on it: our industry, and therefore also the life science sector, are industries of the future. Strengthening them brings multiple benefits. 🎤 How do you perceive Austria as a location for life sciences? 🔊 We have a very good infrastructure in Austria, enormously committed and competent researchers and can therefore also compete internationally in the life science sector. There are many hidden champions in Austria that play a part in the global market or are even global market leaders. The life science sector is really leading the way here! 🎤 What are the trends you observe in the Life Science sector in Austria? 🔊 According to the latest media reports, the total volume of #investment has fallen from 1 billion Euro to 700 million Euro in 2023. At the same time we see a certain awareness at a political level that we have a vibrant and internationally competitive life science sector in Austria. It is therefore all the more important not to threaten this by investing less, but quite the opposite: to keep at it in order to remain internationally competitive. Photo Credit: © Stefan Csaky

Let's talk about your filter needs for your pharmaceutical manufacturing processes such as micronization and fluid bed processing at CPHI next week. I will be at Booth 1605, ready to work with you on the right solution!

Very important information for the #medicalcannabis (or any Life Sciences) industry - engaging with HCP, the people who ultimately determine the success of your product. Invest in Denmark

🎉 Our journey is ongoing to celebrate a milestone in Korean Pharma Innovation 🎉 I would like to share the milestone in the history of Korean pharmaceutical and biotech companies. Our nation has made remarkable strides in the global pharmaceutical landscape, particularly with approvals from the European Medicines Agency (EMA). This success highlights the innovation, dedication, and global competitiveness of Korean companies.Key Achievements: 1. Ontruzant (trastuzumab biosimilar) by Samsung Bioepis, approved by EMA in November 2017. 2. Herzuma (trastuzumab biosimilar) by Celltrion Healthcare, approved in February 2018. 3. Imraldi (adalimumab biosimilar) by Samsung Bioepis, approved in August 2017. 4. Flixabi (infliximab biosimilar) by Samsung Bioepis, approved in May 2016. 5. Fulphila (pegfilgrastim biosimilar) by Mylan and Samsung Bioepis, approved in November 2018. Those approvals not only validate the quality and efficacy of our products but also open doors for further collaboration and innovation on a global scale. In those creative collaborations, I hope we will make further progress and creation. As we continue to develop cutting-edge treatments, the potential for international partnerships is immense. As they made the dramatic history in the short timeline, I believe we can make new achievements in the new era over the biosimilar. Together, we can drive forward the next wave of pharmaceutical innovation, benefiting patients worldwide and solidifying Korea’s position as a leader in the global healthcare market. Let’s connect, collaborate, and innovate for a healthier future! 🤝🌍 #Pharmaceuticals #Biotech #Innovation #Korea #GlobalHealth #Partnerships #HealthcareInnovation #EMA #Biosimilars #FutureOfMedicine #CRO #CNRResearch #ClinicalTrial #EuropCRO #씨엔알리서치 #임상시험 #글로벌임상시험 #국제협력

The Middle East is set to witness the unrivalled force of the pharmaceutical sector as it hosts the 6th Arab Pharma Manufacturers Expo’ the region's largest & premier exhibition on comprehensive Pharma Manufacturing. Mark your calendars for July 2nd and 3rd, 2024, as this dynamic event descends upon the JIEC - Jordan International Exhibition Center at the iconic MECCA MALL in Amman, Jordan. Prepare to be part of history as we present the largest and most impactful edition to date, showcasing the pinnacle of industry advancements and innovations. #sustainablepackaging #recyclability #packaging #sustainability #circulareconomy #recycledmaterials #resourceefficiency #pharmaceuticalpackaging